MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Regulus Therapeutics Company Profile (NASDAQ:RGLS)

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.29 (335.96% upside)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)
Show:
DateFirmActionRatingPrice TargetActions
5/2/2016BMO Capital MarketsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Wells FargoInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016FBR & Co.Reiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2016WedbushReiterated RatingOutperform$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016Chardan CapitalInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2015GuggenheimInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Deutsche BankSet Price TargetBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/29/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha